Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma

International Journal of Hematology, 06/15/2012

CHOP–granulocyte colony stimulating factor (G–CSF) and rituximab (CHOP–GR) is a safe and effective therapy for patients with untreated diffuse large B cell lymphoma (DLBCL).

Print Article Summary Cat 2 CME Report